nodes	percent_of_prediction	percent_of_DWPC	metapath
Trametinib—CYP2C8—Spironolactone—dilated cardiomyopathy	0.236	1	CbGbCtD
Trametinib—Gastric haemorrhage—Spironolactone—dilated cardiomyopathy	0.061	0.22	CcSEcCtD
Trametinib—Rash erythematous—Spironolactone—dilated cardiomyopathy	0.00998	0.036	CcSEcCtD
Trametinib—Hyperkalaemia—Spironolactone—dilated cardiomyopathy	0.00751	0.0271	CcSEcCtD
Trametinib—Hypomagnesaemia—Furosemide—dilated cardiomyopathy	0.00655	0.0236	CcSEcCtD
Trametinib—Renal failure acute—Spironolactone—dilated cardiomyopathy	0.00601	0.0217	CcSEcCtD
Trametinib—Hypocalcaemia—Furosemide—dilated cardiomyopathy	0.00454	0.0164	CcSEcCtD
Trametinib—Renal failure—Spironolactone—dilated cardiomyopathy	0.0042	0.0152	CcSEcCtD
Trametinib—Oropharyngeal pain—Lisinopril—dilated cardiomyopathy	0.00343	0.0124	CcSEcCtD
Trametinib—Creatinine increased—Lisinopril—dilated cardiomyopathy	0.00328	0.0118	CcSEcCtD
Trametinib—Muscle spasms—Spironolactone—dilated cardiomyopathy	0.00321	0.0116	CcSEcCtD
Trametinib—Hyperkalaemia—Lisinopril—dilated cardiomyopathy	0.00307	0.0111	CcSEcCtD
Trametinib—Hyponatraemia—Furosemide—dilated cardiomyopathy	0.00303	0.0109	CcSEcCtD
Trametinib—Leukopenia—Spironolactone—dilated cardiomyopathy	0.00299	0.0108	CcSEcCtD
Trametinib—Blood creatinine increased—Furosemide—dilated cardiomyopathy	0.00283	0.0102	CcSEcCtD
Trametinib—Dehydration—Furosemide—dilated cardiomyopathy	0.00281	0.0101	CcSEcCtD
Trametinib—Hypokalaemia—Furosemide—dilated cardiomyopathy	0.00275	0.0099	CcSEcCtD
Trametinib—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.00267	0.00963	CcSEcCtD
Trametinib—Pancreatitis—Furosemide—dilated cardiomyopathy	0.00256	0.00922	CcSEcCtD
Trametinib—Renal failure acute—Lisinopril—dilated cardiomyopathy	0.00245	0.00884	CcSEcCtD
Trametinib—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.00235	0.00849	CcSEcCtD
Trametinib—Hyperglycaemia—Furosemide—dilated cardiomyopathy	0.00235	0.00849	CcSEcCtD
Trametinib—Renal failure—Furosemide—dilated cardiomyopathy	0.00229	0.00824	CcSEcCtD
Trametinib—Hyponatraemia—Lisinopril—dilated cardiomyopathy	0.00227	0.0082	CcSEcCtD
Trametinib—Pain in extremity—Lisinopril—dilated cardiomyopathy	0.00227	0.00817	CcSEcCtD
Trametinib—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.00216	0.00777	CcSEcCtD
Trametinib—Blood creatinine increased—Lisinopril—dilated cardiomyopathy	0.00212	0.00765	CcSEcCtD
Trametinib—Dehydration—Lisinopril—dilated cardiomyopathy	0.00211	0.00759	CcSEcCtD
Trametinib—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.00206	0.00744	CcSEcCtD
Trametinib—Urethral disorder—Furosemide—dilated cardiomyopathy	0.00205	0.00738	CcSEcCtD
Trametinib—Eye disorder—Furosemide—dilated cardiomyopathy	0.00195	0.00704	CcSEcCtD
Trametinib—Pruritus—Spironolactone—dilated cardiomyopathy	0.00193	0.00696	CcSEcCtD
Trametinib—Pancreatitis—Lisinopril—dilated cardiomyopathy	0.00192	0.00692	CcSEcCtD
Trametinib—Angiopathy—Furosemide—dilated cardiomyopathy	0.00189	0.00683	CcSEcCtD
Trametinib—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.00187	0.00673	CcSEcCtD
Trametinib—Arrhythmia—Furosemide—dilated cardiomyopathy	0.00187	0.00673	CcSEcCtD
Trametinib—Neutropenia—Lisinopril—dilated cardiomyopathy	0.00183	0.0066	CcSEcCtD
Trametinib—Erythema—Furosemide—dilated cardiomyopathy	0.00182	0.00655	CcSEcCtD
Trametinib—Malnutrition—Furosemide—dilated cardiomyopathy	0.00182	0.00655	CcSEcCtD
Trametinib—Dizziness—Spironolactone—dilated cardiomyopathy	0.0018	0.0065	CcSEcCtD
Trametinib—Dysgeusia—Furosemide—dilated cardiomyopathy	0.00178	0.00642	CcSEcCtD
Trametinib—Hyperglycaemia—Lisinopril—dilated cardiomyopathy	0.00177	0.00637	CcSEcCtD
Trametinib—Muscle spasms—Furosemide—dilated cardiomyopathy	0.00175	0.0063	CcSEcCtD
Trametinib—Vomiting—Spironolactone—dilated cardiomyopathy	0.00173	0.00625	CcSEcCtD
Trametinib—Rash—Spironolactone—dilated cardiomyopathy	0.00172	0.0062	CcSEcCtD
Trametinib—Dermatitis—Spironolactone—dilated cardiomyopathy	0.00172	0.00619	CcSEcCtD
Trametinib—Renal failure—Lisinopril—dilated cardiomyopathy	0.00172	0.00619	CcSEcCtD
Trametinib—Vision blurred—Furosemide—dilated cardiomyopathy	0.00171	0.00618	CcSEcCtD
Trametinib—Headache—Spironolactone—dilated cardiomyopathy	0.00171	0.00616	CcSEcCtD
Trametinib—Urinary tract infection—Lisinopril—dilated cardiomyopathy	0.0017	0.00612	CcSEcCtD
Trametinib—Anaemia—Furosemide—dilated cardiomyopathy	0.00168	0.00606	CcSEcCtD
Trametinib—Haematuria—Lisinopril—dilated cardiomyopathy	0.00166	0.006	CcSEcCtD
Trametinib—Epistaxis—Lisinopril—dilated cardiomyopathy	0.00165	0.00594	CcSEcCtD
Trametinib—Leukopenia—Furosemide—dilated cardiomyopathy	0.00163	0.00587	CcSEcCtD
Trametinib—Nausea—Spironolactone—dilated cardiomyopathy	0.00162	0.00584	CcSEcCtD
Trametinib—Bradycardia—Lisinopril—dilated cardiomyopathy	0.0016	0.00575	CcSEcCtD
Trametinib—MAP2K2—cardiac ventricle—dilated cardiomyopathy	0.00159	0.256	CbGeAlD
Trametinib—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.00155	0.00558	CcSEcCtD
Trametinib—Oedema peripheral—Lisinopril—dilated cardiomyopathy	0.00154	0.00557	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.00154	0.00554	CcSEcCtD
Trametinib—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.00154	0.00554	CcSEcCtD
Trametinib—Dry mouth—Furosemide—dilated cardiomyopathy	0.00151	0.00546	CcSEcCtD
Trametinib—MAP2K2—myocardium—dilated cardiomyopathy	0.0015	0.241	CbGeAlD
Trametinib—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.00146	0.00525	CcSEcCtD
Trametinib—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.00145	0.00524	CcSEcCtD
Trametinib—Skin disorder—Furosemide—dilated cardiomyopathy	0.00144	0.0052	CcSEcCtD
Trametinib—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.00143	0.00517	CcSEcCtD
Trametinib—Angiopathy—Lisinopril—dilated cardiomyopathy	0.00142	0.00513	CcSEcCtD
Trametinib—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.00141	0.00509	CcSEcCtD
Trametinib—Chills—Lisinopril—dilated cardiomyopathy	0.00141	0.00507	CcSEcCtD
Trametinib—Arrhythmia—Lisinopril—dilated cardiomyopathy	0.0014	0.00505	CcSEcCtD
Trametinib—Mental disorder—Lisinopril—dilated cardiomyopathy	0.00137	0.00495	CcSEcCtD
Trametinib—Malnutrition—Lisinopril—dilated cardiomyopathy	0.00136	0.00492	CcSEcCtD
Trametinib—Erythema—Lisinopril—dilated cardiomyopathy	0.00136	0.00492	CcSEcCtD
Trametinib—Dysgeusia—Lisinopril—dilated cardiomyopathy	0.00134	0.00482	CcSEcCtD
Trametinib—Back pain—Lisinopril—dilated cardiomyopathy	0.00132	0.00476	CcSEcCtD
Trametinib—Muscle spasms—Lisinopril—dilated cardiomyopathy	0.00131	0.00473	CcSEcCtD
Trametinib—Decreased appetite—Furosemide—dilated cardiomyopathy	0.00129	0.00465	CcSEcCtD
Trametinib—Vision blurred—Lisinopril—dilated cardiomyopathy	0.00129	0.00463	CcSEcCtD
Trametinib—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.00128	0.00462	CcSEcCtD
Trametinib—Fatigue—Furosemide—dilated cardiomyopathy	0.00128	0.00461	CcSEcCtD
Trametinib—Constipation—Furosemide—dilated cardiomyopathy	0.00127	0.00457	CcSEcCtD
Trametinib—Anaemia—Lisinopril—dilated cardiomyopathy	0.00126	0.00455	CcSEcCtD
Trametinib—Leukopenia—Lisinopril—dilated cardiomyopathy	0.00122	0.0044	CcSEcCtD
Trametinib—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.00121	0.00437	CcSEcCtD
Trametinib—Cough—Lisinopril—dilated cardiomyopathy	0.00119	0.00429	CcSEcCtD
Trametinib—MAP2K1—heart—dilated cardiomyopathy	0.00119	0.191	CbGeAlD
Trametinib—Abdominal pain—Furosemide—dilated cardiomyopathy	0.00117	0.00423	CcSEcCtD
Trametinib—Body temperature increased—Furosemide—dilated cardiomyopathy	0.00117	0.00423	CcSEcCtD
Trametinib—Myalgia—Lisinopril—dilated cardiomyopathy	0.00116	0.00419	CcSEcCtD
Trametinib—Arthralgia—Lisinopril—dilated cardiomyopathy	0.00116	0.00419	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.00115	0.00416	CcSEcCtD
Trametinib—Dry mouth—Lisinopril—dilated cardiomyopathy	0.00114	0.00409	CcSEcCtD
Trametinib—Oedema—Lisinopril—dilated cardiomyopathy	0.00111	0.00401	CcSEcCtD
Trametinib—Infection—Lisinopril—dilated cardiomyopathy	0.00111	0.00399	CcSEcCtD
Trametinib—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.00109	0.00393	CcSEcCtD
Trametinib—Skin disorder—Lisinopril—dilated cardiomyopathy	0.00108	0.0039	CcSEcCtD
Trametinib—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.00108	0.00388	CcSEcCtD
Trametinib—Asthenia—Furosemide—dilated cardiomyopathy	0.00106	0.00384	CcSEcCtD
Trametinib—Pruritus—Furosemide—dilated cardiomyopathy	0.00105	0.00378	CcSEcCtD
Trametinib—MAP2K2—heart—dilated cardiomyopathy	0.00105	0.168	CbGeAlD
Trametinib—Diarrhoea—Furosemide—dilated cardiomyopathy	0.00102	0.00366	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.00101	0.00366	CcSEcCtD
Trametinib—Insomnia—Lisinopril—dilated cardiomyopathy	0.00101	0.00363	CcSEcCtD
Trametinib—Dizziness—Furosemide—dilated cardiomyopathy	0.000981	0.00354	CcSEcCtD
Trametinib—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.000968	0.00349	CcSEcCtD
Trametinib—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.000961	0.00347	CcSEcCtD
Trametinib—Fatigue—Lisinopril—dilated cardiomyopathy	0.00096	0.00346	CcSEcCtD
Trametinib—Constipation—Lisinopril—dilated cardiomyopathy	0.000952	0.00343	CcSEcCtD
Trametinib—Vomiting—Furosemide—dilated cardiomyopathy	0.000943	0.0034	CcSEcCtD
Trametinib—Rash—Furosemide—dilated cardiomyopathy	0.000936	0.00337	CcSEcCtD
Trametinib—Dermatitis—Furosemide—dilated cardiomyopathy	0.000935	0.00337	CcSEcCtD
Trametinib—Headache—Furosemide—dilated cardiomyopathy	0.00093	0.00335	CcSEcCtD
Trametinib—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.00091	0.00328	CcSEcCtD
Trametinib—MAP2K2—cardiac atrium—dilated cardiomyopathy	0.000895	0.144	CbGeAlD
Trametinib—Nausea—Furosemide—dilated cardiomyopathy	0.000881	0.00318	CcSEcCtD
Trametinib—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.00088	0.00317	CcSEcCtD
Trametinib—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.00088	0.00317	CcSEcCtD
Trametinib—Asthenia—Lisinopril—dilated cardiomyopathy	0.000799	0.00288	CcSEcCtD
Trametinib—Pruritus—Lisinopril—dilated cardiomyopathy	0.000788	0.00284	CcSEcCtD
Trametinib—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.000762	0.00275	CcSEcCtD
Trametinib—Dizziness—Lisinopril—dilated cardiomyopathy	0.000736	0.00265	CcSEcCtD
Trametinib—Vomiting—Lisinopril—dilated cardiomyopathy	0.000708	0.00255	CcSEcCtD
Trametinib—Rash—Lisinopril—dilated cardiomyopathy	0.000702	0.00253	CcSEcCtD
Trametinib—Dermatitis—Lisinopril—dilated cardiomyopathy	0.000701	0.00253	CcSEcCtD
Trametinib—Headache—Lisinopril—dilated cardiomyopathy	0.000697	0.00251	CcSEcCtD
Trametinib—Nausea—Lisinopril—dilated cardiomyopathy	0.000661	0.00238	CcSEcCtD
Trametinib—MAP2K1—EGF/EGFR Signaling Pathway—RAC1—dilated cardiomyopathy	0.000509	0.00106	CbGpPWpGaD
Trametinib—MAP2K1—B Cell Receptor Signaling Pathway—RAF1—dilated cardiomyopathy	0.000509	0.00106	CbGpPWpGaD
Trametinib—MAP2K2—Fc epsilon receptor (FCERI) signaling—RAC1—dilated cardiomyopathy	0.000507	0.00105	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 interactions—RAC1—dilated cardiomyopathy	0.000507	0.00105	CbGpPWpGaD
Trametinib—MAP2K1—MAPK Signaling Pathway—FAS—dilated cardiomyopathy	0.000504	0.00105	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 signaling—RAC1—dilated cardiomyopathy	0.000504	0.00105	CbGpPWpGaD
Trametinib—MAP2K2—VEGFA-VEGFR2 Pathway—RAF1—dilated cardiomyopathy	0.000503	0.00105	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by Interleukins—RAF1—dilated cardiomyopathy	0.000499	0.00104	CbGpPWpGaD
Trametinib—MAP2K1—Integrin-mediated Cell Adhesion—RAF1—dilated cardiomyopathy	0.000497	0.00103	CbGpPWpGaD
Trametinib—MAP2K1—MAPK Signaling Pathway—RAC1—dilated cardiomyopathy	0.000494	0.00103	CbGpPWpGaD
Trametinib—MAP2K2—Downstream signaling in naïve CD8+ T cells—TNF—dilated cardiomyopathy	0.000483	0.00101	CbGpPWpGaD
Trametinib—MAP2K2—Focal Adhesion—RAC1—dilated cardiomyopathy	0.000479	0.000996	CbGpPWpGaD
Trametinib—MAP2K1—ErbB1 downstream signaling—RAF1—dilated cardiomyopathy	0.000478	0.000993	CbGpPWpGaD
Trametinib—MAP2K1—Senescence and Autophagy in Cancer—RAF1—dilated cardiomyopathy	0.000478	0.000993	CbGpPWpGaD
Trametinib—MAP2K1—AGE/RAGE pathway—EGFR—dilated cardiomyopathy	0.000475	0.000988	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by VEGF—RAF1—dilated cardiomyopathy	0.000475	0.000987	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 interactions—RAC1—dilated cardiomyopathy	0.000474	0.000986	CbGpPWpGaD
Trametinib—MAP2K1—Fc epsilon receptor (FCERI) signaling—RAC1—dilated cardiomyopathy	0.000474	0.000986	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	0.000472	0.000982	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by Insulin receptor—RAF1—dilated cardiomyopathy	0.000471	0.00098	CbGpPWpGaD
Trametinib—MAP2K1—VEGFA-VEGFR2 Pathway—RAF1—dilated cardiomyopathy	0.00047	0.000978	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by Interleukins—RAF1—dilated cardiomyopathy	0.000467	0.000971	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	0.000455	0.000947	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signaling in naïve CD8+ T cells—TNF—dilated cardiomyopathy	0.000452	0.000941	CbGpPWpGaD
Trametinib—MAP2K1—Focal Adhesion—RAC1—dilated cardiomyopathy	0.000448	0.000932	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	0.000446	0.000928	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by VEGF—RAF1—dilated cardiomyopathy	0.000444	0.000924	CbGpPWpGaD
Trametinib—MAP2K2—PDGFR-beta signaling pathway—RAF1—dilated cardiomyopathy	0.000444	0.000923	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—PSEN2—dilated cardiomyopathy	0.000443	0.000922	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000442	0.00092	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by Insulin receptor—RAF1—dilated cardiomyopathy	0.000441	0.000917	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways in Glioblastoma—EGFR—dilated cardiomyopathy	0.000427	0.000887	CbGpPWpGaD
Trametinib—MAP2K2—TGF-beta Signaling Pathway—RAF1—dilated cardiomyopathy	0.000425	0.000884	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000416	0.000865	CbGpPWpGaD
Trametinib—MAP2K1—PDGFR-beta signaling pathway—RAF1—dilated cardiomyopathy	0.000415	0.000864	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—PSEN2—dilated cardiomyopathy	0.000415	0.000863	CbGpPWpGaD
Trametinib—MAP2K2—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—dilated cardiomyopathy	0.000415	0.000862	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by SCF-KIT—RAF1—dilated cardiomyopathy	0.000403	0.000839	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways in Glioblastoma—EGFR—dilated cardiomyopathy	0.000399	0.00083	CbGpPWpGaD
Trametinib—MAP2K2—MicroRNAs in cardiomyocyte hypertrophy—TNF—dilated cardiomyopathy	0.000398	0.000829	CbGpPWpGaD
Trametinib—MAP2K1—TGF-beta Signaling Pathway—RAF1—dilated cardiomyopathy	0.000398	0.000827	CbGpPWpGaD
Trametinib—MAP2K2—BDNF signaling pathway—RAF1—dilated cardiomyopathy	0.000396	0.000825	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—ITGB1—dilated cardiomyopathy	0.000389	0.000809	CbGpPWpGaD
Trametinib—MAP2K1—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—dilated cardiomyopathy	0.000388	0.000807	CbGpPWpGaD
Trametinib—MAP2K2—Downstream signaling of activated FGFR—RAF1—dilated cardiomyopathy	0.000386	0.000802	CbGpPWpGaD
Trametinib—MAP2K2—Regulation of Actin Cytoskeleton—RAF1—dilated cardiomyopathy	0.000386	0.000802	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by ERBB4—RAF1—dilated cardiomyopathy	0.00038	0.00079	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by SCF-KIT—RAF1—dilated cardiomyopathy	0.000377	0.000785	CbGpPWpGaD
Trametinib—MAP2K2—L1CAM interactions—EGFR—dilated cardiomyopathy	0.000376	0.000782	CbGpPWpGaD
Trametinib—MAP2K1—MicroRNAs in cardiomyocyte hypertrophy—TNF—dilated cardiomyopathy	0.000373	0.000775	CbGpPWpGaD
Trametinib—MAP2K1—BDNF signaling pathway—RAF1—dilated cardiomyopathy	0.000371	0.000772	CbGpPWpGaD
Trametinib—MAP2K2—Insulin Signaling—RAF1—dilated cardiomyopathy	0.000364	0.000758	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—ITGB1—dilated cardiomyopathy	0.000364	0.000757	CbGpPWpGaD
Trametinib—MAP2K2—Downstream signal transduction—RAF1—dilated cardiomyopathy	0.000363	0.000754	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signaling of activated FGFR—RAF1—dilated cardiomyopathy	0.000361	0.000751	CbGpPWpGaD
Trametinib—MAP2K1—Regulation of Actin Cytoskeleton—RAF1—dilated cardiomyopathy	0.000361	0.000751	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR—RAF1—dilated cardiomyopathy	0.000361	0.00075	CbGpPWpGaD
Trametinib—MAP2K2—EGF/EGFR Signaling Pathway—RAF1—dilated cardiomyopathy	0.000361	0.00075	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by ERBB2—RAF1—dilated cardiomyopathy	0.000359	0.000747	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 signaling—RAF1—dilated cardiomyopathy	0.000357	0.000743	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB4—RAF1—dilated cardiomyopathy	0.000355	0.000739	CbGpPWpGaD
Trametinib—MAP2K1—L1CAM interactions—EGFR—dilated cardiomyopathy	0.000352	0.000732	CbGpPWpGaD
Trametinib—MAP2K2—MAPK Signaling Pathway—RAF1—dilated cardiomyopathy	0.00035	0.000729	CbGpPWpGaD
Trametinib—MAP2K2—ErbB1 downstream signaling—EGFR—dilated cardiomyopathy	0.00035	0.000728	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—RAC1—dilated cardiomyopathy	0.000345	0.000718	CbGpPWpGaD
Trametinib—MAP2K2—Toll-like Receptor Signaling Pathway—TNF—dilated cardiomyopathy	0.000341	0.00071	CbGpPWpGaD
Trametinib—MAP2K1—Insulin Signaling—RAF1—dilated cardiomyopathy	0.000341	0.000709	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signal transduction—RAF1—dilated cardiomyopathy	0.000339	0.000706	CbGpPWpGaD
Trametinib—MAP2K1—EGF/EGFR Signaling Pathway—RAF1—dilated cardiomyopathy	0.000338	0.000702	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR—RAF1—dilated cardiomyopathy	0.000338	0.000702	CbGpPWpGaD
Trametinib—MAP2K2—Fc epsilon receptor (FCERI) signaling—RAF1—dilated cardiomyopathy	0.000336	0.000699	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 interactions—RAF1—dilated cardiomyopathy	0.000336	0.000699	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR in disease—RAF1—dilated cardiomyopathy	0.000336	0.000699	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB2—RAF1—dilated cardiomyopathy	0.000336	0.000699	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 signaling—RAF1—dilated cardiomyopathy	0.000334	0.000695	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR—RAF1—dilated cardiomyopathy	0.000333	0.000693	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR in Cancer—RAF1—dilated cardiomyopathy	0.00033	0.000687	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by PDGF—RAF1—dilated cardiomyopathy	0.000329	0.000684	CbGpPWpGaD
Trametinib—MAP2K1—MAPK Signaling Pathway—RAF1—dilated cardiomyopathy	0.000328	0.000682	CbGpPWpGaD
Trametinib—MAP2K1—ErbB1 downstream signaling—EGFR—dilated cardiomyopathy	0.000327	0.000681	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—RAC1—dilated cardiomyopathy	0.000323	0.000672	CbGpPWpGaD
Trametinib—MAP2K1—Toll-like Receptor Signaling Pathway—TNF—dilated cardiomyopathy	0.000319	0.000664	CbGpPWpGaD
Trametinib—MAP2K2—Focal Adhesion—RAF1—dilated cardiomyopathy	0.000318	0.000661	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR in disease—RAF1—dilated cardiomyopathy	0.000314	0.000654	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 interactions—RAF1—dilated cardiomyopathy	0.000314	0.000654	CbGpPWpGaD
Trametinib—MAP2K1—Fc epsilon receptor (FCERI) signaling—RAF1—dilated cardiomyopathy	0.000314	0.000654	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—RAC1—dilated cardiomyopathy	0.000313	0.00065	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR—RAF1—dilated cardiomyopathy	0.000312	0.000648	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR in Cancer—RAF1—dilated cardiomyopathy	0.000309	0.000643	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by PDGF—RAF1—dilated cardiomyopathy	0.000308	0.00064	CbGpPWpGaD
Trametinib—MAP2K2—NGF signalling via TRKA from the plasma membrane—RAF1—dilated cardiomyopathy	0.000298	0.000619	CbGpPWpGaD
Trametinib—MAP2K1—Focal Adhesion—RAF1—dilated cardiomyopathy	0.000297	0.000618	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	0.000296	0.000615	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—RAC1—dilated cardiomyopathy	0.000292	0.000608	CbGpPWpGaD
Trametinib—MAP2K2—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—dilated cardiomyopathy	0.000288	0.000598	CbGpPWpGaD
Trametinib—MAP2K1—NGF signalling via TRKA from the plasma membrane—RAF1—dilated cardiomyopathy	0.000279	0.000579	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—ITGB1—dilated cardiomyopathy	0.000277	0.000577	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by SCF-KIT—EGFR—dilated cardiomyopathy	0.000276	0.000575	CbGpPWpGaD
Trametinib—MAP2K1—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—dilated cardiomyopathy	0.000269	0.00056	CbGpPWpGaD
Trametinib—MAP2K2—Regulation of toll-like receptor signaling pathway—TNF—dilated cardiomyopathy	0.000266	0.000554	CbGpPWpGaD
Trametinib—MAP2K2—Regulation of Actin Cytoskeleton—EGFR—dilated cardiomyopathy	0.000265	0.00055	CbGpPWpGaD
Trametinib—MAP2K2—Downstream signaling of activated FGFR—EGFR—dilated cardiomyopathy	0.000265	0.00055	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by ERBB4—EGFR—dilated cardiomyopathy	0.00026	0.000542	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—ITGB1—dilated cardiomyopathy	0.00026	0.00054	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by SCF-KIT—EGFR—dilated cardiomyopathy	0.000259	0.000538	CbGpPWpGaD
Trametinib—MAP2K1—Regulation of toll-like receptor signaling pathway—TNF—dilated cardiomyopathy	0.000249	0.000518	CbGpPWpGaD
Trametinib—MAP2K2—Downstream signal transduction—EGFR—dilated cardiomyopathy	0.000249	0.000517	CbGpPWpGaD
Trametinib—MAP2K1—Regulation of Actin Cytoskeleton—EGFR—dilated cardiomyopathy	0.000248	0.000515	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signaling of activated FGFR—EGFR—dilated cardiomyopathy	0.000248	0.000515	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR—EGFR—dilated cardiomyopathy	0.000247	0.000515	CbGpPWpGaD
Trametinib—MAP2K2—EGF/EGFR Signaling Pathway—EGFR—dilated cardiomyopathy	0.000247	0.000515	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by ERBB2—EGFR—dilated cardiomyopathy	0.000246	0.000512	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 signaling—EGFR—dilated cardiomyopathy	0.000245	0.00051	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB4—EGFR—dilated cardiomyopathy	0.000244	0.000507	CbGpPWpGaD
Trametinib—MAP2K2—MAPK Signaling Pathway—EGFR—dilated cardiomyopathy	0.00024	0.0005	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—CD36—dilated cardiomyopathy	0.000237	0.000492	CbGpPWpGaD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—RAF1—dilated cardiomyopathy	0.000233	0.000484	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signal transduction—EGFR—dilated cardiomyopathy	0.000233	0.000484	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR—EGFR—dilated cardiomyopathy	0.000231	0.000481	CbGpPWpGaD
Trametinib—MAP2K1—EGF/EGFR Signaling Pathway—EGFR—dilated cardiomyopathy	0.000231	0.000481	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR in disease—EGFR—dilated cardiomyopathy	0.00023	0.000479	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 interactions—EGFR—dilated cardiomyopathy	0.00023	0.000479	CbGpPWpGaD
Trametinib—MAP2K2—Fc epsilon receptor (FCERI) signaling—EGFR—dilated cardiomyopathy	0.00023	0.000479	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB2—EGFR—dilated cardiomyopathy	0.00023	0.000479	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 signaling—EGFR—dilated cardiomyopathy	0.000229	0.000477	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—RAF1—dilated cardiomyopathy	0.000229	0.000476	CbGpPWpGaD
Trametinib—MAP2K2—MAPK Signaling Pathway—TNF—dilated cardiomyopathy	0.000229	0.000476	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR—EGFR—dilated cardiomyopathy	0.000228	0.000475	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR in Cancer—EGFR—dilated cardiomyopathy	0.000226	0.000471	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by PDGF—EGFR—dilated cardiomyopathy	0.000225	0.000469	CbGpPWpGaD
Trametinib—MAP2K1—MAPK Signaling Pathway—EGFR—dilated cardiomyopathy	0.000225	0.000468	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—RAC1—dilated cardiomyopathy	0.000223	0.000464	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000222	0.000461	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000222	0.000461	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—CD36—dilated cardiomyopathy	0.000221	0.000461	CbGpPWpGaD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—RAF1—dilated cardiomyopathy	0.000218	0.000453	CbGpPWpGaD
Trametinib—MAP2K2—Focal Adhesion—EGFR—dilated cardiomyopathy	0.000218	0.000453	CbGpPWpGaD
Trametinib—MAP2K2—Disease—NPPA—dilated cardiomyopathy	0.000217	0.000452	CbGpPWpGaD
Trametinib—MAP2K1—Fc epsilon receptor (FCERI) signaling—EGFR—dilated cardiomyopathy	0.000216	0.000449	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 interactions—EGFR—dilated cardiomyopathy	0.000216	0.000449	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR in disease—EGFR—dilated cardiomyopathy	0.000216	0.000449	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—RAF1—dilated cardiomyopathy	0.000214	0.000446	CbGpPWpGaD
Trametinib—MAP2K1—MAPK Signaling Pathway—TNF—dilated cardiomyopathy	0.000214	0.000445	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR—EGFR—dilated cardiomyopathy	0.000214	0.000445	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR in Cancer—EGFR—dilated cardiomyopathy	0.000212	0.000441	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by PDGF—EGFR—dilated cardiomyopathy	0.000211	0.000439	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PSEN2—dilated cardiomyopathy	0.000211	0.000438	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—CD36—dilated cardiomyopathy	0.000209	0.000435	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—RAC1—dilated cardiomyopathy	0.000209	0.000434	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000207	0.000431	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000207	0.000431	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—RAF1—dilated cardiomyopathy	0.000207	0.000431	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000206	0.000429	CbGpPWpGaD
Trametinib—MAP2K2—NGF signalling via TRKA from the plasma membrane—EGFR—dilated cardiomyopathy	0.000204	0.000425	CbGpPWpGaD
Trametinib—MAP2K1—Focal Adhesion—EGFR—dilated cardiomyopathy	0.000204	0.000424	CbGpPWpGaD
Trametinib—MAP2K1—Disease—NPPA—dilated cardiomyopathy	0.000203	0.000423	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	0.000203	0.000422	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.0002	0.000415	CbGpPWpGaD
Trametinib—MAP2K2—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	0.000197	0.00041	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PSEN2—dilated cardiomyopathy	0.000197	0.00041	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—ANKRD1—dilated cardiomyopathy	0.000197	0.00041	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—RAC1—dilated cardiomyopathy	0.000197	0.00041	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—CD36—dilated cardiomyopathy	0.000196	0.000407	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—RAF1—dilated cardiomyopathy	0.000194	0.000403	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	0.000193	0.000402	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000193	0.000401	CbGpPWpGaD
Trametinib—MAP2K1—NGF signalling via TRKA from the plasma membrane—EGFR—dilated cardiomyopathy	0.000191	0.000397	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000187	0.000388	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—TAZ—dilated cardiomyopathy	0.000185	0.000385	CbGpPWpGaD
Trametinib—MAP2K1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	0.000185	0.000384	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—RAC1—dilated cardiomyopathy	0.000184	0.000383	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.00017	0.000355	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—SDHA—dilated cardiomyopathy	0.000168	0.000348	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.000162	0.000336	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000159	0.000332	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—EGFR—dilated cardiomyopathy	0.000157	0.000327	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.000151	0.000315	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—RAF1—dilated cardiomyopathy	0.000148	0.000308	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000147	0.000307	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—EGFR—dilated cardiomyopathy	0.000147	0.000306	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—ITGB1—dilated cardiomyopathy	0.000143	0.000297	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—EGFR—dilated cardiomyopathy	0.000142	0.000296	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—RAF1—dilated cardiomyopathy	0.000138	0.000288	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000138	0.000287	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—ITGB1—dilated cardiomyopathy	0.000134	0.000278	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—EGFR—dilated cardiomyopathy	0.000133	0.000277	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000131	0.000272	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000131	0.000272	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—RAF1—dilated cardiomyopathy	0.000131	0.000272	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000126	0.000261	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000123	0.000255	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000123	0.000255	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—RAF1—dilated cardiomyopathy	0.000122	0.000254	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000122	0.000253	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CD36—dilated cardiomyopathy	0.000122	0.000253	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—AGT—dilated cardiomyopathy	0.00012	0.00025	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000118	0.000245	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000117	0.000244	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—RAC1—dilated cardiomyopathy	0.000115	0.000239	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000114	0.000237	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CD36—dilated cardiomyopathy	0.000114	0.000237	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—AGT—dilated cardiomyopathy	0.000112	0.000233	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.00011	0.000229	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—RAC1—dilated cardiomyopathy	0.000107	0.000223	CbGpPWpGaD
Trametinib—MAP2K2—Disease—RAC1—dilated cardiomyopathy	0.000106	0.00022	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ANKRD1—dilated cardiomyopathy	0.000106	0.00022	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	0.000102	0.000213	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—EGFR—dilated cardiomyopathy	0.000101	0.000211	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000101	0.000209	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	9.95e-05	0.000207	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—TAZ—dilated cardiomyopathy	9.94e-05	0.000207	CbGpPWpGaD
Trametinib—MAP2K1—Disease—RAC1—dilated cardiomyopathy	9.91e-05	0.000206	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—TNF—dilated cardiomyopathy	9.66e-05	0.000201	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—ADRB2—dilated cardiomyopathy	9.55e-05	0.000199	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—EGFR—dilated cardiomyopathy	9.49e-05	0.000197	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—AGTR1—dilated cardiomyopathy	9.42e-05	0.000196	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—TNF—dilated cardiomyopathy	9.04e-05	0.000188	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—SDHA—dilated cardiomyopathy	8.99e-05	0.000187	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	8.96e-05	0.000186	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—EGFR—dilated cardiomyopathy	8.96e-05	0.000186	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—ADRB2—dilated cardiomyopathy	8.94e-05	0.000186	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—EGFR—dilated cardiomyopathy	8.38e-05	0.000174	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—RAF1—dilated cardiomyopathy	8.33e-05	0.000173	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	8.21e-05	0.000171	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—RAF1—dilated cardiomyopathy	7.79e-05	0.000162	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	7.68e-05	0.00016	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—RAF1—dilated cardiomyopathy	7.61e-05	0.000158	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—RAC1—dilated cardiomyopathy	7.42e-05	0.000154	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—RAF1—dilated cardiomyopathy	7.12e-05	0.000148	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—AGT—dilated cardiomyopathy	7.09e-05	0.000147	CbGpPWpGaD
Trametinib—MAP2K2—Disease—RAF1—dilated cardiomyopathy	7.02e-05	0.000146	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—RAC1—dilated cardiomyopathy	6.94e-05	0.000144	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—AGT—dilated cardiomyopathy	6.63e-05	0.000138	CbGpPWpGaD
Trametinib—MAP2K1—Disease—RAF1—dilated cardiomyopathy	6.57e-05	0.000137	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—EGFR—dilated cardiomyopathy	5.71e-05	0.000119	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—EGFR—dilated cardiomyopathy	5.34e-05	0.000111	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—EGFR—dilated cardiomyopathy	5.22e-05	0.000108	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—RAF1—dilated cardiomyopathy	4.92e-05	0.000102	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—EGFR—dilated cardiomyopathy	4.88e-05	0.000102	CbGpPWpGaD
Trametinib—MAP2K2—Disease—EGFR—dilated cardiomyopathy	4.82e-05	0.0001	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—RAF1—dilated cardiomyopathy	4.6e-05	9.57e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—GPX1—dilated cardiomyopathy	4.55e-05	9.46e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—EGFR—dilated cardiomyopathy	4.51e-05	9.37e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CD36—dilated cardiomyopathy	4.43e-05	9.22e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—AGT—dilated cardiomyopathy	3.99e-05	8.3e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—EGFR—dilated cardiomyopathy	3.37e-05	7.01e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—EGFR—dilated cardiomyopathy	3.16e-05	6.56e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GPX1—dilated cardiomyopathy	2.44e-05	5.08e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CD36—dilated cardiomyopathy	2.38e-05	4.95e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—AGT—dilated cardiomyopathy	2.14e-05	4.45e-05	CbGpPWpGaD
